News >

Strategies Emerging for PARP Inhibitor Resistance in Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Wednesday, Aug 28, 2019

Kathleen N.
Moore, MD

Kathleen N. Moore, MD
Although the addition of three FDA-approved PARP inhibitors has been game-changing to ovarian cancer treatment, a multitude of unanswered questions remain regarding whether patients can be rechallenged with a PARP inhibitor upon resistance, explained Kathleen Moore, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Publication Bottom Border
Border Publication